Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: A systematic review and meta-analysis

Vaccine

Volumn 31, Issue 45, 2013, Pages 5168-5177

  Breteler, Janna K ^a,b   Tam, John S ^a   Jit, Mark ^c,d   Ket, Johannes C F ^b   De Boer, Michiel R ^b,e  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

COPD; Developing countries; Effectiveness; Efficacy; HIC; ILI; Influenza; LIC; LMIC; MIC,; RCT; Vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PLACEBO;

2009 H1N1 INFLUENZA; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COHORT ANALYSIS; DRUG EFFICACY; EMBASE; EVIDENCE BASED MEDICINE; FOLLOW UP; GERIATRIC PATIENT; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; INFLUENZA VACCINATION; LABORATORY DIAGNOSIS; LOWEST INCOME GROUP; MEDLINE; META ANALYSIS; MIDDLE INCOME GROUP; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEASONAL INFLUENZA; SOCIAL STATUS; SYSTEMATIC REVIEW;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COPD; DEVELOPING COUNTRIES; EFFECTIVENESS; EFFICACY; HIC; HIGH INCOME COUNTRY; ILI; INFLUENZA; INFLUENZA-LIKE ILLNESS; LIC; LMIC; LOW AND MIDDLE INCOME COUNTRY; LOW INCOME COUNTRY; MIC,; MIDDLE INCOME COUNTRY; RANDOMIZED CONTROLLED TRIAL; RCT; VACCINE;

CORONARY DISEASE; DEVELOPING COUNTRIES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS;

EID: 84885948261     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.056     Document Type: Review

References (76)

1. Dawood F.S., Fry A., Muangchana C., Sanasuttipun W., Baggett H.C., Chunsuttiwat S., et al. A method for estimating vaccine-preventable pediatric influenza pneumonia hospitalizations in developing countries: Thailand as a case study. Vaccine 2011, [accessed 17.07.13]. 10.1016/S1473-3099(12)70121-4.
2. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999, 17(Suppl. 1):S3-S10.
3. Gessner B.D., Shindo N., Briand S. Seasonal influenza epidemiology in sub-Saharan Africa: a systematic review. Lancet Infectious Diseases 2011, 11(3):223-235.
4. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378(9807):1917-1930.
5. The Macroepidemiology of Influenza Vaccination (MIV) Study Group The macro-epidemiology of influenza vaccination in 56 countries, 1997-2003. Vaccine 2005, 23(44):5133-5143.
6. Palache A. Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. Vaccine 2011, 29(51):9459-9466.
7. Ropero-Alvarez A.M., Kurtis H.J., Danovaro-Holliday M.C., Ruiz-Matus C., Andrus J.K. Expansion of seasonal influenza vaccination in the Americas. BMC Public Health 2009, 9:361.
8. Van Essen G.A., Palache A.M., Forleo E., Fedson D.S. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 2003, 21(16):1780-1785.
9. SAGE Working Group Background Paper on Influenza Vaccines and Immunization 2012, [accessed 05.12.12]. http://www.who.int/influenza/vaccines/SAGE_information/en/index.html.
10. World Health Organization Vaccines against influenza WHO position paper - November 2012. Weekly Epidemiological Record 2012, 47(87):461-476.
11. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 2003, 21(16):1769-1775.
12. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases 2012, 12(1):36-44.
13. Poland G.A., Rottinghaus S.T., Jacobson R.M. Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 2001, 19(17-19):2216-2220.
14. World Health Organization Influenza Vaccines WHO Position Paper. Weekly Epidemiological Record 2005, 33:279-287.
15. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2008, 2:CD004879.
16. Manzoli L., Schioppa F., Boccia A., Villari P. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatric Infectious Disease Journal 2007, 26(2):97-106.
17. Jefferson T., Di Pietrantonj C., Rivetti A., Bawazeer G.A., Al-Ansary L.A., Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2010, 7:CD001269.
18. Atashili J., Kalilani L., Adimora A.A. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infectious Diseases 2006, 6:138.
19. Cates C.J., Jefferson T.O., Rowe B.H. Vaccines for preventing influenza in people with asthma. Cochrane Database of Systematic Reviews 2008, 2:CD000364.
20. Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, 1:CD002733.
21. Da Cunha S.S., Camacho L.A., Santos A.C., Dourado I. Influenza vaccination in Brazil: rationale and caveats. Revista de saude publica 2005, 39(1):129-136.
22. Luna E.J., Gattas V.L. Effectiveness of the Brazilian influenza vaccination policy, a systematic review. Revista do Instituto de Medicina Tropical de Sao Paulo 2010, 52(4):175-181.
23. Ortiz J.R., Englund J.A., Neuzil K.M. Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. Vaccine 2011, 29(27):4439-4452.
24. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine 2008, 26(49):6232-6236.
25. Menon B., Gurnani M., Aggarwal B. Comparison of outpatient visits and hospitalisations, in patients with chronic obstructive pulmonary disease, before and after influenza vaccination. International Journal of Clinical Practice 2008, 62(4):593-598.
26. Qureshi H., Gessner B.D., Leboulleux D., Hasan H., Alam S.E., Moulton L.H. The incidence of vaccine preventable influenza-like illness and medication use among Pakistani pilgrims to the Haj in Saudi Arabia. Vaccine 2000, 18(26):2956-2962.
27. Zaman K., Roy E., Arifeen S.E., Rahman M., Raqib R., Wilson E., et al. Effectiveness of maternal influenza immunization in mothers and infants. New England Journal of Medicine 2008, 359(15):1555-1564.
28. Wu J., Xu F., Lu L., et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. New England Journal of Medicine 2010, 363(25):2416-2423.
29. Bracco Neto H., Farhat C.K., Tregnaghi M.W., Madhi S.A., Razmpour A., Palladino G., et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatric Infectious Disease Journal 2009, 28(5):365-371.
30. Khan A.S., Polezhaev F., Vasiljeva R., Drinevsky V., Buffington J., Gary H., et al. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. Journal of Infectious Diseases 1996, 173(2):453-456.
31. Slepushkin A.N., Obrosova-Serova N.P., Burtseva E.I., Rudenko L.G., Govorkova E.A., Vartanyan R.V., et al. Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987/88. Vaccine 1993, 11(3):323-328.
32. Tam J.S., Capeding M.R., Lum L.C.S., Chotpitayasunondh T., Jiang Z., Huang L.M., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatric Infectious Disease Journal 2007, 26(7):619-628.
33. Teodorovici G., Ivan A., Petrescu A., Mihail A., Cajal N. Epidemiological evaluation of the protection conferred by the Nivgrip vaccine against influenza caused by the A(H1N1) virus. Virologie 1982, 33(4):279-282.
34. Jianping H., Xin F., Changshun L., Bo Z., Linxiu G., Wei X., et al. Assessment of effectiveness of Vaxigrip. Vaccine 1999, 17(Suppl. 1):S57-S58.
35. Teodorovici G., Ivan A., Vieriu V., Duman F., Stenter M., Frunzareanu N., et al. Epidemiological evaluation of the protection conferred by the Nivgrip vaccine against influenza caused by the A(H3N2) virus. Virologie 1984, 35(1):39-41.
36. Rudenko L.G., Slepushkin A.N., Monto A.S., Kendal A.P., Grigorieva E.P., Burtseva E.P., et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. Journal of Infectious Diseases 1993, 168(4):881-887.
37. Rudenko L.G., Lonskaya N.I., Klimov A.I., Vasilieva R.I., Ramirez A. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bulletin of the World Health Organization 1996, 74(1):77-84.
38. Ozgur S.K., Beyazova U., Kemaloglu Y.K., Maral I., Sahin F., Camurdan A.D., et al. Effectiveness of inactivated influenza vaccine for prevention of otitis media in children. Pediatric Infectious Disease Journal 2006, 25(5):401-404.
39. Steiner N., Mihailescu M., Grigore N., Anghelescu S., Ene R. Immunofluorescence study on the prevalence of some respiratory viruses in subjects vaccinated against influenza and in unvaccinated controls. Virologie 1985, 36(4):289-293.
40. Mixeu M.A., Vespa G.N., Forleo-Neto E., Toniolo-Neto J., Alves P.M. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviation Space and Environmental Medicine 2002, 73(9):876-880.
41. At'kov O.Y., Azarov A.V., Zhukov D.A., Nicoloyannis N., Durand L. Influenza vaccination in healthy working adults in Russia: observational study of effectiveness and return on investment for the employer. Applied Health Economics and Health Policy 2011, 9(2):89-99.
42. Morales A., Martinez M.M., Tasset-Tisseau A., Rey E., Baron-Papillon F., Follet A. Costs and benefits of influenza vaccination and work productivity in a Colombian company from the employer's perspective. ValueHealth 2004, 7(4):433-441.
43. Samad A.H., Usul M.H.B.H., Zakaria D., Ismail R., Tasset-Tisseau A., Baron-Papillon F., et al. Workplace vaccination against influenza in Malaysia: does the employer benefit?. Journal of Occupational Health 2006, 48(1):1-10.
44. Steiner N., Petrescu A., Teodosiu O., Mihail A., Mihailescu M., Steiner G., et al. Influenza vaccination by nasal route in a semi-closed community. Virologie 1980, 31(2):117-120.
45. Wood S.C., Alexseiv A., Nguyen V.H. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 1999, 17(Suppl. 3):S81-S87.
46. Steiner N., Petrescu A., Mihail A., Steiner G., Calina A. Morbidity by upper respiratory tract diseases in a semi-closed community, after intranasal application of an inactivated influenza vaccine. Virologie 1981, 32(4):307-309.
47. Mesa Duque S.S., Perez Moreno A., Hurtado G., Arbelaez Montoya M.P. Effectiveness of an influenza vaccine in a working population in Colombia. Revista Panamericana de Salud Publica 2001, 10(4):232-239.
48. De Villiers P.J.T., Steele A.D., Hiemstra L.A., Rappaport R., Dunning A.J., Gruber W.C., et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009, 28(1):228-234.
49. Rudenko L.G., Arden N.H., Grigorieva E., Naychin A., Rekstin A., Klimov A.I., et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000, 19(2-3):308-318.
50. Praditsuwan R., Assantachai P., Wasi C., Puthavatana P., Kositanont U. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. Journal of the Medical Association of Thailand 2005, 88(2):256-264.
51. Forrest B.D., Steele A.D., Hiemstra L., Rappaport R., Ambrose C.S., Gruber W.C. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 2011, 29(20):3633-3639.
52. Isahak I., Mahayiddin A.A., Ismail R. Effectiveness of influenza vaccination in prevention of influenza-like illness among inhabitants of old folk homes. Southeast Asian Journal of Tropical Medicine and Public Health 2007, 38(5):841-848.
53. Plasai V., Lertmaharit S., Viputsiri O.A., Pongpanich S., Panichpathompong U., Tarnmaneewongse V., et al. Influenza vaccination among the elderly in Bangkok. Southeast Asian Journal of Tropical Medicine and Public Health 2006, 37(Suppl. 3):140-144.
54. Gutierrez E.B., Li H.Y., Santos A.C., Lopes M.H. Effectiveness of influenza vaccination in elderly outpatients in Sao Paulo city, Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo 2001, 43(6):317-320.
55. Stamboulian D., Bonvehi P.E., Nacinovich F.M., Ruttimann R.W. Immunization against influenza in the elderly: the Argentinian experience, 1993-1997. Vaccine 1999, 17(Suppl. 1):S53-S56.
56. Van Vuuren A., Rheeder P., Hak E. Effectiveness of influenza vaccination in the elderly in South Africa. Epidemiology and Infection 2009, 137(7):994-1002.
57. Madhi S.A., Maskew M., Koen A., Kuwanda L., Besselaar T.G., Naidoo D., et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clinical Infectious Diseases 2011, 52(1):128-137.
58. Gurfinkel E.P., de la Fuente R.L., Mendiz O., Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002, 105(18):2143-2147.
59. Gurfinkel E.P., Leon de la F.R., Mendiz O., Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. European Heart Journal 2004, 25(1):25-31.
60. Phrommintikul A., Kuanprasert S., Wongcharoen W., Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. European Heart Journal 2010, 31:372-373.
61. Gurfinkel E.P., de la Fuente R.L. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry. Texas Heart Institute Journal/from the Texas Heart Institute of StLuke's Episcopal Hospital, Texas Children's Hospital 2004, 31(1):28-32.
62. Mustafa A.N., Gessner B.D., Ismail R., Yusoff A.F., Abdullah N., Ishak I., et al. A case-control study of influenza vaccine effectiveness among Malaysian pilgrims attending the Haj in Saudi Arabia. International Journal of Infectious Diseases 2003, 7(3):210-214.
63. Kositanont U., Kanyok R., Wasi C., Wongsurakiat P., Suthamsmai T., Maranetra N. Occurrence and protective level of influenza infections using serology in patients with COPD in vaccination study. Journal of the Medical Association of Thailand 2004, 87(8):964-969.
64. Wongsurakiat P., Maranetra K.N., Wasi C., Kositanont U., Dejsomritrutai W., Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004, 125(6):2011-2020.
65. Abadoglu O., Mungan D., Pasaoglu G., Celik G., Misirligil Z. Influenza vaccination in patients with asthma: effect on the frequency of upper respiratory tract infections and exacerbations. Journal of Asthma 2004, 41(3):279-283.
66. Machado C.M., Cardoso M.R., da Rocha I., Boas L.S., Dulley F.L., Pannuti C.S. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplantation 2005, 36(10):897-900.
67. Vesikari T., Fleming D.M., Aristegui J.F., Vertruyen A., Ashkenazi S., Rappaport R., et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118(6):2298-2312.
68. Keller T., Weeda V.B., van Dongen C.J., Levi M. Influenza vaccines for preventing coronary heart disease. Cochrane Database of Systematic Reviews 2008, 3. CD005050.
69. Ciszewski A., Bilinska Z.T., Brydak L.B., Kepka C., Kruk M., Romanowska M., et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. European Heart Journal 2008, 29(11):1350-1358.
70. Hauck T.S., Giri S., Gao Y., Chan W.C. Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Advanced Drug Delivery Reviews 2010, 62(4-5):438-448.
71. Belongia E.A., Kieke B.A., Donahue J.G., Greenlee R.T., Balish A., Foust A., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. Journal of Infectious Diseases 2009, 199(2):159-167.
72. Nichol K.L. Efficacy and effectiveness of influenza vaccination. Vaccine 2008, 26(Suppl. 4):D17-D22.
73. Beyer W.E. Heterogeneity of case definitions used in vaccine effectiveness studies-and its impact on meta-analysis. Vaccine 2006, 24(44-46):6602-6604.
74. Nichol K.L. Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine 2006, 44-46:6726-6728.
75. Glezen W.P. Herd protection against influenza. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2006, 37(4):237-243.
76. Viboud C., Simonsen L. Global mortality of 2009 pandemic influenza A H1N1. Lancet Infectious Diseases 2012, 12(9):651-653.